12/08/2026
The Substantia Nigra:
The substantia nigra β Latin for "black substance" β is a small paired nucleus in the midbrain that appears macroscopically dark due to the melanin pigment in its dopaminergic neurons, and serves as the primary producer of dopamine for the nigrostriatal pathway that modulates voluntary movement through its projections to the striatum of the basal ganglia. It is divided into the pars compacta (SNc, containing the dopamine-producing neurons) and the pars reticulata (SNr, a GABAergic output nucleus), and its dopaminergic modulation of striatal circuits determines the balance between movement facilitation and suppression that underlies smooth, coordinated voluntary action. Parkinson's disease is characterized by the progressive, selective degeneration of SNc dopaminergic neurons β by the time motor symptoms appear, approximately 60 to 70% of these neurons have already been lost, because the remaining neurons compensate until a critical threshold is breached β producing the cardinal features of tremor, rigidity, bradykinesia, and postural instability. Lewy bodies β abnormal aggregations of misfolded alpha-synuclein protein within dopaminergic neurons β are the pathological hallmark of Parkinson's disease and related synucleinopathies, and current research into prion-like spread of alpha-synuclein aggregates from the gut and nose to the brain (the Braak staging hypothesis) is reshaping understanding of Parkinson's as potentially an environmental disease of gut-brain axis origin. The dramatic efficacy of L-DOPA (levodopa), the dopamine precursor that crosses the blood-brain barrier and is converted to dopamine in remaining SNc neurons, remains the cornerstone of Parkinson's treatment over 50 years after its introduction β a testament to how precisely its mechanism targets the fundamental pathophysiology.